It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Sandoz: A leader in patient access, savings, and manufacturing1-6

Sandoz is a proven leader

First biosimilar to surpass its reference product in market share6

  • More than 50 million patient-exposure days in 100 countries7,8
  • ZARXIO has the most unrestricted combined medical and pharmacy benefit coverage in the SA G-CSF class9-11*
  • Demonstrated cost-effectiveness as primary prophylaxis to decrease the incidence of chemotherapy-induced febrile neutropenia in cancer patients2,12
  • Real-world evidence of savings across IDNs, payers, and patients4,13-15

*"Most" defined as a comparison to NEUPOGEN®, Granix®, RELEUKO®, and NIVESTYM® in terms of combined medical and pharmacy benefit status. "Unrestricted" defined as on formulary, managed to Prescribing Information, and not requiring prior authorization and step edits. Coverage defined as "Exclusive or Co-Preferred" on commercial, Medicare, health exchange plans, and pharmacy benefit managers (PBMs) on pharmacy benefit, and commercial, Medicare, and health exchange plans on medical benefit according to Managed Markets Insight & Technology (MMIT) data as of January 2023.9-11

ZARXIO cost savings may liberate healthcare resources and expand patient access

~$2.9 billion savings were driven by biosimilar filgrastim2†

Cost savings chart
Net cost savings chart with biosimilar in the fligrstim market

Biosimilars allow for expanded patient access and potential savings for patients, helping alleviate the overburdened healthcare system16-17

Sandoz is committed to bringing biosimilars to more patients around the world

  • Strong investment in manufacturing: End-to-end technical capabilities ensure the reliable development, manufacturing, and supply of industry-leading, quality biosimilars
  • Robust pipeline: With 8 approved biosimilars in Europe, as well as a strong development pipeline, Sandoz will continue to leverage its global expertise in the US18
  • Proven track record: First company to bring biosimilars to patients in both the US and worldwide1,9

Learn about ZIEXTENZO (pegfilgrastim-bmez), the long-acting G-CSF treatment option from Sandoz15

G-CSF=granulocyte colony-stimulating factor; IDN=integrated delivery network; SA=short-acting.

NEUPOGEN is a registered trademark of Amgen Inc.
Granix is a registered trademark of Teva Pharmaceutical Industries Ltd.
NIVESTYM is a registered trademark of Pfizer Inc.
RELEUKO is a registered trademark of KASHIV BIOSCIENCES, LLC.

References: 1. Helfand C. FDA approves first biosimilar product Zarxio. Fierce Pharma. Published March 6, 2015. Accessed November 21, 2022. 2. Data on file. Filgrastim Net Sales Analysis Model. Sandoz Inc. January 2023. 3. Wang W, Campbell K, Balu S. Cost­minimization analysis for biosimilar pegfilgrastim in the prophylaxis of chemotherapy induced (febrile) neutropenia and expanded access based on budget neutral basis. J Clin Oncol. 2019;37(suppI 15):6645. doi:10.1200/JCO.2019.37.15_suppl.6645. 4. Puckrein G, Xu Liu, Ryan A, Campbell K, Balu S. Potential Medicare beneficiary out-of-pocket reductions through using biosimilar filgrastim-sndz over reference filgrastim: a simulation analysis. Poster presented at: AMCP Nexus; October 22-25, 2018; Orlando, Florida. 5. Data on file. Novartis Manufacturing Manual Version 2.0. Sandoz Inc. 6. Data on file. ZARXIO and ZIEXTENZO Market Share Analysis. Sandoz Inc. March 2023. 7. Data on file. Sandoz Biosimilar PSUR Data. Sandoz Inc. May 2022. 8. Data on File. Princeton NJ: Sandoz Inc; December 2020. 9. Data on file. Zitter Sandoz Neutropenia Commercial Pharmacy and Medical Coverage Analysis. Princeton, NJ: Sandoz Inc; 2019. 10. Short Acting Filgrastim Medical Coverage. Yardley, PA: MMIT; April 2023. 11. Short Acting Filgrastim Pharmacy Coverage. Yardley, PA: MMIT; April 2023. 12. ZARXIO Prescribing Information. Sandoz Inc. September 2022. 13. Leber MB, Abdelghany O, Miller L. Biosimilar adoption: health system challenges and strategies for success. Presented at: 2016 Vizient Clinical Connections Summit: September 29, 2016; Dallas, TX. 14. Trautman H, Szabo E, James E, Tang B. Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective. J Manag Care Spec Pharm. 2019;25:94-101.
15. McBride A, Balu S, Campbell K, et al. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. Future Oncol. 2017;13:2285-2295. 16. IQVIA Institute for Human Data Science. The Global Use of Medicine in 2019 and Outlook to 2023. Published January 29, 2019. Accessed August 13, 2019. 17. Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for delivery at the Brookings Institution on the release of the FDA’s Biosimilar Action Plan [press release]. Rockville, MD: US Food and Drug Administration; July 18, 2018. 18. Grover N., Scheer S. Generic drugmakers Teva and Sandoz make major push to biosimilars. Reuters website. Published November 22, 2022. Accessed March 30, 2023. 19. Data on file. Periodic Safety Update Report (PSUR) for somatropin – containing products, April 1, 2017 ⎼ September 30, 2017. Sandoz Inc. November 2017. 20. ZIEXTENZO Prescribing Information. Sandoz Inc. March 2021.